Education
About Us
Working with TipRanks
Follow Us
Percheron Therapeutics Limited (AU:PER)
:PER
Total Valuation
Percheron Therapeutics has a market cap or net worth of AU$8.70M. The enterprise value is -AU$3.02M.
Market CapAU$8.70M
Enterprise Value-AU$3.02M
Share Statistics
Percheron Therapeutics has 1,087,437,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,087,437,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Percheron Therapeutics’s return on equity (ROE) is -1.49 and return on invested capital (ROIC) is -151.63%.
Return on Equity (ROE)-1.49
Return on Assets (ROA)-1.20
Return on Invested Capital (ROIC)-151.63%
Return on Capital Employed (ROCE)-1.67
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Percheron Therapeutics is ―. Percheron Therapeutics’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio1.02
Price to Fair Value1.02
Price to FCF-0.65
Price to Operating Cash Flow-0.52
PEG Ratio0.04
Income Statement
In the last 12 months, Percheron Therapeutics had revenue of 0.00 and earned -14.92M in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit-67.98K
Operating Income-16.71M
Pretax Income-16.35M
Net Income-14.92M
EBITDA-16.27M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -15.64M and capital expenditures -7.24K, giving a free cash flow of -15.65M billion.
Operating Cash Flow-15.64M
Free Cash Flow-15.65M
Free Cash Flow per Share-0.01
Dividends & Yields
Percheron Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.16
52-Week Price Change-85.71%
50-Day Moving Average0.01
200-Day Moving Average―
Relative Strength Index (RSI)47.47
Average Volume (3m)2.41M
Important Dates
Percheron Therapeutics upcoming earnings date is Feb 25, 2026, TBA (Confirmed).
Last Earnings DateAug 28, 2025
Next Earnings DateFeb 25, 2026
Ex-Dividend Date―
Financial Position
Percheron Therapeutics as a current ratio of 5.10, with Debt / Equity ratio of 0.26%
Current Ratio5.10
Quick Ratio5.10
Debt to Market Cap<0.01
Net Debt to EBITDA0.62
Interest Coverage Ratio-1.12K
Taxes
In the past 12 months, Percheron Therapeutics has paid -1.43M in taxes.
Income Tax-1.43M
Effective Tax Rate0.09
Enterprise Valuation
Percheron Therapeutics EV to EBITDA ratio is >-0.01, with an EV/FCF ratio of >-0.01.
EV to Sales0.00
EV to EBITDA>-0.01
EV to Free Cash Flow>-0.01
EV to Operating Cash Flow>-0.01
Balance Sheet
Percheron Therapeutics has AU$10.17M in cash and marketable securities with AU$25.86K in debt, giving a net cash position of AU$10.14M billion.
Cash & Marketable SecuritiesAU$10.17M
Total DebtAU$25.86K
Net CashAU$10.14M
Net Cash Per Share<AU$0.01
Tangible Book Value Per Share<AU$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Percheron Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―